3514 related articles for article (PubMed ID: 32849662)
21. The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19.
Braendstrup P; Levine BL; Ruella M
Cytotherapy; 2020 Feb; 22(2):57-69. PubMed ID: 32014447
[TBL] [Abstract][Full Text] [Related]
22. Role of chimeric antigen receptor T-cell therapy: bridge to transplantation or stand-alone therapy in pediatric acute lymphoblastic leukemia.
Qayed M; Bleakley M; Shah NN
Curr Opin Hematol; 2021 Nov; 28(6):373-379. PubMed ID: 34508031
[TBL] [Abstract][Full Text] [Related]
23. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.
Cai B; Guo M; Wang Y; Zhang Y; Yang J; Guo Y; Dai H; Yu C; Sun Q; Qiao J; Hu K; Zuo H; Dong Z; Zhang Z; Feng M; Li B; Sun Y; Liu T; Liu Z; Wang Y; Huang Y; Yao B; Han W; Ai H
J Hematol Oncol; 2016 Nov; 9(1):131. PubMed ID: 27887660
[TBL] [Abstract][Full Text] [Related]
24. CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease.
Lu W; Wei Y; Cao Y; Xiao X; Li Q; Lyu H; Jiang Y; Zhang H; Li X; Jiang Y; Meng J; Yuan T; Zhu H; He X; Jin X; Sun R; Sui T; Liu K; Zhao M
Cancer Immunol Immunother; 2021 Dec; 70(12):3501-3511. PubMed ID: 33899130
[TBL] [Abstract][Full Text] [Related]
25. Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia.
Myers RM; Devine K; Li Y; Lawrence S; Leahy AB; Liu H; Vernau L; Callahan C; Baniewicz D; Kadauke S; McGuire R; Wertheim GB; Kulikovskaya I; Gonzalez VE; Fraietta JA; DiNofia AM; Hunger SP; Rheingold SR; Aplenc R; June CH; Grupp SA; Wray L; Maude SL
Blood Adv; 2024 May; 8(9):2182-2192. PubMed ID: 38386999
[TBL] [Abstract][Full Text] [Related]
26. In Like a Lamb; Out Like a Lion: Marching CAR T Cells Toward Enhanced Efficacy in B-ALL.
Safarzadeh Kozani P; Safarzadeh Kozani P; O'Connor RS
Mol Cancer Ther; 2021 Jul; 20(7):1223-1233. PubMed ID: 33903140
[TBL] [Abstract][Full Text] [Related]
27. A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia.
Weng J; Lai P; Qin L; Lai Y; Jiang Z; Luo C; Huang X; Wu S; Shao D; Deng C; Huang L; Lu Z; Zhou M; Zeng L; Chen D; Wang Y; Chen X; Geng S; Robert W; Tang Z; He C; Li P; Du X
J Hematol Oncol; 2018 Feb; 11(1):25. PubMed ID: 29458388
[TBL] [Abstract][Full Text] [Related]
28. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
Cappell KM; Sherry RM; Yang JC; Goff SL; Vanasse DA; McIntyre L; Rosenberg SA; Kochenderfer JN
J Clin Oncol; 2020 Nov; 38(32):3805-3815. PubMed ID: 33021872
[TBL] [Abstract][Full Text] [Related]
29. Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
Chen YH; Zhang X; Cheng YF; Chen H; Mo XD; Yan CH; Chen Y; Han W; Sun YQ; Wang Y; Zhang XH; Xu LP; Liu KY; Yang J; Zhang J; Zhang GL; Shi Y; Su YC; Li WQ; Xu L; Song D; Zhang M; Lu P; Huang XJ
Cytotherapy; 2020 Dec; 22(12):755-761. PubMed ID: 32861622
[TBL] [Abstract][Full Text] [Related]
30. Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art.
Abramson JS; Lunning M; Palomba ML
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():446-453. PubMed ID: 31099671
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
32. CAR T-cells in acute lymphoblastic leukemia: Current results.
Dourthe ME; Baruchel A
Bull Cancer; 2021 Oct; 108(10S):S40-S54. PubMed ID: 34920807
[TBL] [Abstract][Full Text] [Related]
33. CAR T-cell therapy effective in B acute lymphoblastic leukaemia.
Wang M
Lancet Oncol; 2017 Jun; 18(6):e314. PubMed ID: 28528746
[No Abstract] [Full Text] [Related]
34. CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial.
Cordoba S; Onuoha S; Thomas S; Pignataro DS; Hough R; Ghorashian S; Vora A; Bonney D; Veys P; Rao K; Lucchini G; Chiesa R; Chu J; Clark L; Fung MM; Smith K; Peticone C; Al-Hajj M; Baldan V; Ferrari M; Srivastava S; Jha R; Arce Vargas F; Duffy K; Day W; Virgo P; Wheeler L; Hancock J; Farzaneh F; Domning S; Zhang Y; Khokhar NZ; Peddareddigari VGR; Wynn R; Pule M; Amrolia PJ
Nat Med; 2021 Oct; 27(10):1797-1805. PubMed ID: 34642489
[TBL] [Abstract][Full Text] [Related]
35. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.
Liu S; Deng B; Yin Z; Lin Y; An L; Liu D; Pan J; Yu X; Chen B; Wu T; Chang AH; Tong C
Am J Hematol; 2021 Jun; 96(6):671-679. PubMed ID: 33725422
[TBL] [Abstract][Full Text] [Related]
36. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
[TBL] [Abstract][Full Text] [Related]
37. CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR.
Shalabi H; Qin H; Su A; Yates B; Wolters PL; Steinberg SM; Ligon JA; Silbert S; DéDé K; Benzaoui M; Goldberg S; Achar S; Schneider D; Shahani SA; Little L; Foley T; Molina JC; Panch S; Mackall CL; Lee DW; Chien CD; Pouzolles M; Ahlman M; Yuan CM; Wang HW; Wang Y; Inglefield J; Toledo-Tamula MA; Martin S; Highfill SL; Altan-Bonnet G; Stroncek D; Fry TJ; Taylor N; Shah NN
Blood; 2022 Aug; 140(5):451-463. PubMed ID: 35605184
[TBL] [Abstract][Full Text] [Related]
38. Strategies for having a more effective and less toxic CAR T-cell therapy for acute lymphoblastic leukemia.
Hashem Boroojerdi M; Rahbarizadeh F; Safarzadeh Kozani P; Kamali E; Safarzadeh Kozani P
Med Oncol; 2020 Oct; 37(11):100. PubMed ID: 33047234
[TBL] [Abstract][Full Text] [Related]
39. Advances in the development of chimeric antigen receptor-T-cell therapy in B-cell acute lymphoblastic leukemia.
Zhang X; Li JJ; Lu PH
Chin Med J (Engl); 2020 Feb; 133(4):474-482. PubMed ID: 31977556
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies.
Xu X; Sun Q; Liang X; Chen Z; Zhang X; Zhou X; Li M; Tu H; Liu Y; Tu S; Li Y
Front Immunol; 2019; 10():2664. PubMed ID: 31798590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
